Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent hemodialysis
Fritz Sörgel(West German Heart and Vascular Center Essen), Jan Rybniker(University of Cologne), Jakob J Malin(University of Cologne), Uwe Fuhr(University of Cologne), Henning Hagmann(University of Cologne), Oliver Scherf‐Clavel(University of Würzburg), Dennis A. Eichenauer(University of Cologne), Lobna El Tabei(University of Cologne), Muhammad Bilal(University of Cologne), Alexander Simonis(University of Cologne), Martina Kinzig(Institute for Biomedical and Pharmaceutical Research)
Cited by 9
Related Papers
Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19
|EMBO Molecular Medicine|2021|154
Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells
|Leukemia|2020|90
A comparative analysis of remdesivir and other repurposed antivirals against SARS‐CoV‐2
|EMBO Molecular Medicine|2020|86